Compare IDEXX Laboratories, Inc. (IDXX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Xcel Energy Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Xcel Energy Inc trades at $73.78 (market cap $45.82B). The key difference: IDEXX Laboratories, Inc. and Xcel Energy Inc are close in size by market cap, and Xcel Energy Inc pays a 3.23% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Xcel Energy Inc for 61 Days on average.
| IDXX | XEL | |
|---|---|---|
Market Cap | $40.43B | $45.82B |
Volume | 692,164 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $766.68 | $83.91 |
52-Week Low | $504.70 | $69.39 |
Typical Hold Time | 46 Days | 61 Days |
Enterprise Value | $41.32B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Xcel Energy (XEL) trades at $73.78, up 1.87% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growing data center power demand and a $60B capital investment plan driving future growth. Analyst consensus remains positive with a $90.83 price target representing 23% upside potential.
XEL offers attractive total return potential through earnings growth and dividend yield, supported by regulated utility business model and infrastructure investments. Key risks include wildfire liabilities, rising interest rates impacting financing costs, and execution challenges with large capital projects. The stock presents a balanced opportunity for income and growth investors seeking utility exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
